Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial

EXCLI Journal

Ruslinda Mustafar¹  Mohd Noor Azreey Mukri²  Wei-Yen Kong³ 

[1] Department of Community Health, UKM Medical Molecular Biology Institute, Jalan Yaakob Latif, Bandar Tun Razak, Cheras 56000, Kuala Lumpur, Malaysia;Nephrology Unit, Department of Medicine, National University of Malaysia, Jalan Yaakob Latif, Bandar Tun Razak, Cheras 56000, Kuala Lumpur, Malaysia;Rheumatology Unit, Department of Medicine, National University of Malaysia, Jalan Yaakob Latif, Bandar Tun Razak, Cheras 56000, Kuala Lumpur, Malaysia

关键词: febuxostat;    proteinuria;    chronic kidney failure;    HbA1c;    hyperuricemia;   

DOI  :  10.17179/excli2018-1256

学科分类：过敏症与临床免疫学

来源: University of Mainz, University of Leipzig

【 摘 要 】

Introduction: Hyperuricemia is associated with chronic kidney disease (CKD) progression and poor cardiovascular outcomes. We studied the effect of febuxostat on estimated glomerular filtration rate (eGFR), proteinuria and monitored the safety profile of the medication.

【 授权许可】

CC BY